CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 205 enrolled
Drug / intervention
Brimonidinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02249065
NCT02249065Phase 4Completed
CompareCT.gov

MIRVASO® In Use Study: Managing Rosacea Through Assessment and Control of Its Erythema (The MIRACLE Study)

Galderma R&D·interventional·Posted Sep 25, 2014·Updated Aug 1, 2022

In Brief

A Phase 4 clinical trial evaluating Brimonidine for Rosacea. Completed, enrolled 205 participants across 12 sites.

Detailed Summary

This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment 3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 25, 2014
Enrollment StartSep 1, 2014
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.8 years ago

Interventions

Brimonidinedrug